PURPOSE: To provide patients and physicians with population-based estimates of mortality from prostate cancer or other causes depending upon the primary treatment modality, stratified by patient age, tumor stage and grade. METHODS: We conducted a 10-year competing-risk analysis of 45,440 men diagnosed with clinically localized (T1 or T2) prostate cancer in California during 1995-1998. Information on patient characteristics, primary treatment and cause of death was obtained from the California Cancer Registry. RESULTS: In this population-based cohort, the most common primary treatment was surgery (40.4%), followed by radiotherapy (29.1%), conservative management (20.8%), and androgen deprivation therapy (ADT) monotherapy (9.8%). Prostate cancer mortality differed significantly (p < 0.0001) across treatment groups among patients <80 years at diagnosis with moderately or poorly differentiated disease; the 10-year disease-specific mortality rates were generally highest for men treated with ADT monotherapy [range: 3.3% (95% CI=0.8-12.5%) to 53.8% (95% CI=34.4-72.2%)], intermediate for men treated with conservative management [range: 1.7% (95% CI=0.7-4.6%) to 30.0% (95% CI=16.2-48.8%] or radiotherapy [range: 3.2% (95% CI=1.8-5.5%) to 18.3% (95% CI=15.1-22.0%)], and lowest for men treated with surgery [range: 1.2% (95% CI=0.8-1.7%) to 11.0% (95% CI=8.4-14.2%)]. CONCLUSION: The cause-specific mortality estimates provided by this observational study can help patients and physicians better understand the expected long-term outcomes of localized prostate cancer given the initial treatment choice and practice patterns in the general population.
PURPOSE: To provide patients and physicians with population-based estimates of mortality from prostate cancer or other causes depending upon the primary treatment modality, stratified by patient age, tumor stage and grade. METHODS: We conducted a 10-year competing-risk analysis of 45,440 men diagnosed with clinically localized (T1 or T2) prostate cancer in California during 1995-1998. Information on patient characteristics, primary treatment and cause of death was obtained from the California Cancer Registry. RESULTS: In this population-based cohort, the most common primary treatment was surgery (40.4%), followed by radiotherapy (29.1%), conservative management (20.8%), and androgen deprivation therapy (ADT) monotherapy (9.8%). Prostate cancer mortality differed significantly (p < 0.0001) across treatment groups among patients <80 years at diagnosis with moderately or poorly differentiated disease; the 10-year disease-specific mortality rates were generally highest for men treated with ADT monotherapy [range: 3.3% (95% CI=0.8-12.5%) to 53.8% (95% CI=34.4-72.2%)], intermediate for men treated with conservative management [range: 1.7% (95% CI=0.7-4.6%) to 30.0% (95% CI=16.2-48.8%] or radiotherapy [range: 3.2% (95% CI=1.8-5.5%) to 18.3% (95% CI=15.1-22.0%)], and lowest for men treated with surgery [range: 1.2% (95% CI=0.8-1.7%) to 11.0% (95% CI=8.4-14.2%)]. CONCLUSION: The cause-specific mortality estimates provided by this observational study can help patients and physicians better understand the expected long-term outcomes of localized prostate cancer given the initial treatment choice and practice patterns in the general population.
Entities:
Keywords:
California Cancer Registry; Prostate cancer; cohort study; mortality; treatment
Authors: Mark S Soloway; Kapil Pareek; Rooholiah Sharifi; Zev Wajsman; David McLeod; David P Wood; Antonio Puras-Baez Journal: J Urol Date: 2002-01 Impact factor: 7.450
Authors: Anna Bill-Axelson; Lars Holmberg; Mirja Ruutu; Hans Garmo; Jennifer R Stark; Christer Busch; Stig Nordling; Michael Häggman; Swen-Olof Andersson; Stefan Bratell; Anders Spångberg; Juni Palmgren; Gunnar Steineck; Hans-Olov Adami; Jan-Erik Johansson Journal: N Engl J Med Date: 2011-05-05 Impact factor: 91.245
Authors: David S Yee; William T Lowrance; James A Eastham; Alexandra C Maschino; Angel M Cronin; Farhang Rabbani Journal: BJU Int Date: 2009-07-08 Impact factor: 5.588
Authors: Anthony L Zietman; Kyounghwa Bae; Jerry D Slater; William U Shipley; Jason A Efstathiou; John J Coen; David A Bush; Margie Lunt; Daphna Y Spiegel; Rafi Skowronski; B Rodney Jabola; Carl J Rossi Journal: J Clin Oncol Date: 2010-02-01 Impact factor: 44.544
Authors: Ithaar H Derweesh; Patrick A Kupelian; Craig Zippe; Howard S Levin; Jennifer Brainard; Cristina Magi-Galluzzi; Jonathan Myles; Alwyn M Reuther; Eric A Klein Journal: Urol Oncol Date: 2004 Jul-Aug Impact factor: 3.498
Authors: Grace L Lu-Yao; Peter C Albertsen; Dirk F Moore; Weichung Shih; Yong Lin; Robert S DiPaola; Siu-Long Yao Journal: JAMA Date: 2008-07-09 Impact factor: 56.272
Authors: Philip V Barbosa; I-Chun Thomas; Sandy Srinivas; Mark K Buyyounouski; Benjamin I Chung; Glenn M Chertow; Steven M Asch; Todd H Wagner; James D Brooks; John T Leppert Journal: Eur Urol Date: 2016-03-02 Impact factor: 20.096
Authors: Marianne Schmid; Christian P Meyer; Gally Reznor; Toni K Choueiri; Julian Hanske; Jesse D Sammon; Firas Abdollah; Felix K H Chun; Adam S Kibel; Reginald D Tucker-Seeley; Philip W Kantoff; Stuart R Lipsitz; Mani Menon; Paul L Nguyen; Quoc-Dien Trinh Journal: JAMA Oncol Date: 2016-01 Impact factor: 31.777
Authors: Yunee Kim; Jouhyun Jeon; Salvador Mejia; Cindy Q Yao; Vladimir Ignatchenko; Julius O Nyalwidhe; Anthony O Gramolini; Raymond S Lance; Dean A Troyer; Richard R Drake; Paul C Boutros; O John Semmes; Thomas Kislinger Journal: Nat Commun Date: 2016-06-28 Impact factor: 14.919